Armata Pharmaceuticals, Inc.

ARMP · NYSE American

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders67.6%

Institutions13.5%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$36.63M	-$42.44M	-$40.89M	-$23.82M	-$21.59M	-$19.75M	-$12.52M	-$16.16M	-$23.38M	-$10.23M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$173.80M	-$18.92M	-$69.05M	-$23.16M	-$22.18M	-$19.48M	-$12.11M	-$12.84M	-$18.84M	-$516000
Net income divided by the number of shares outstanding — profit attributable to each share.	$-4.80	$-0.52	$-1.00	$-0.96	$-1.35	$-2.49	$0.00	$-2.00	$-2.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-4.80	$-0.89	$-1.00	$-0.96	$-1.35	$-2.55	$0.00	$-2.00	–	$-1.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$8.70M	$9.30M	$13.50M	$10.29M	$9.65M	$6.03M	$8.16M	$5.13M	$5.71M	$9.37M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$76.88M	$86.44M	$98.36M	$69.77M	–	$25.45M	$11.89M	$11.14M	$18.20M	$31.49M
All of the company's interest-bearing borrowings, short and long term combined.	–	$38.95M	–	–	–	–	–	–	$803000	–
Everything the company owes — debt, unpaid bills, and other obligations.	$295.48M	$134.46M	$130.43M	$44.37M	–	$10.86M	$3.41M	$3.41M	$8.47M	$6.89M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$218.60M	-$48.02M	-$32.06M	$25.40M	–	$14.59M	$8.47M	$7.73M	$9.72M	$12.71M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$25.76M	-$37.55M	-$47.42M	-$23.57M	-$18.27M	-$15.58M	-$9.38M	-$9.19M	-$10.59M	-$9.78M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$542000	$1.88M	$8.14M	$1.30M	$824000	$224000	$44000	$58000	$279000	$210000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$26.30M	-$39.43M	-$55.57M	-$24.88M	-$19.09M	-$15.81M	-$9.43M	-$9.25M	-$10.87M	-$9.99M

	You	Peer avg
Revenue Growth	+15.7%	+186.9%
ROE	–	-75.8%

Armata Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison